Spinal neuroimmune activation is independent of T-cell infiltration and attenuated by A3 adenosine receptor agonists in a model of oxaliplatin-induced peripheral neuropathy

Brain, Behavior, and Immunity

Volumn 44, Issue , 2015, Pages 91-99

  Janes, Kali ^a   Wahlman, Carrie ^a   Little, Joshua W ^a   Doyle, Timothy ^a   Tosh, Dillip K ^b   Jacobson, Kenneth A ^b   Salvemini, Daniela ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

A3 adenosine receptor; Adenosine; Astrocytes; Chemotherapy induced peripheral neuropathy; Neuroinflammation; Neuropathic pain; Oxaliplatin; Spinal cord

Indexed keywords

6 ETHYL 2 PHENYL 4 PROPYL 3 PYRIDINECARBOXYLIC ACID 5 THIOCARBOXYLIC ACID 5 ETHYL 3 PROPYL ESTER; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE A3 RECEPTOR AGONIST; ANTINEOPLASTIC AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; MRS 5698; OXALIPLATIN; PACLITAXEL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; PLATINUM COMPLEX;

ANIMAL EXPERIMENT; ARTICLE; ASTROCYTE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; LYMPHOCYTIC INFILTRATION; MALE; NEUROMODULATION; NEUROPATHIC PAIN; NONHUMAN; PERIPHERAL NEUROPATHY; RAT; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; HYPERALGESIA; IMMUNOLOGY; METABOLISM; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSIOLOGY; SPINAL CORD DORSAL HORN; SPRAGUE DAWLEY RAT;

ADENOSINE A3 RECEPTOR AGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; CYTOKINES; DISEASE MODELS, ANIMAL; HYPERALGESIA; MALE; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD DORSAL HORN; T-LYMPHOCYTES;

EID: 84918578946     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2014.08.010     Document Type: Article

References (72)

1. Abbracchio M.P., Rainaldi G., Giammarioli A.M., Ceruti S., Brambilla R., Cattabeni F., Barbieri D., Franceschi C., Jacobson K.A., Malorni W. The A3 adenosine receptor mediates cell spreading, reorganization of actin cytoskeleton, and distribution of Bcl-XL: studies in human astroglioma cells. Biochem. Biophys. Res. Commun. 1997, 241(2):297-304.
2. Argyriou A.A., Polychronopoulos P., Iconomou G., Chroni E., Kalofonos H.P. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat. Rev. 2008, 34(4):368-377.
3. Austin P.J., Kim C.F., Perera C.J., Moalem-Taylor G. Regulatory T cells attenuate neuropathic pain following peripheral nerve injury and experimental autoimmune neuritis. Pain 2012, 153(9):1916-1931.
4. Ballarin M., Fredholm B.B., Ambrosio S., Mahy N. Extracellular levels of adenosine and its metabolites in the striatum of awake rats: inhibition of uptake and metabolism. Acta Physiol. Scand. 1991, 142(1):97-103.
5. Bar-Yehuda S., Stemmer S.M., Madi L., Castel D., Ochaion A., Cohen S., Barer F., Zabutti A., Perez-Liz G., Del Valle L., et al. The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int. J. Oncol. 2008, 33(2):287-295.
6. Bar-Yehuda S., Luger D., Ochaion A., Cohen S., Patokaa R., Zozulya G., Silver P.B., de Morales J.M., Caspi R.R., Fishman P. Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101. Int. J. Mol. Med. 2011, 28(5):727-731.
7. Bennett G.J., Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988, 33(1):87-107.
8. Boison D. Adenosine kinase: exploitation for therapeutic gain. Pharmacol. Rev. 2013, 65(3):906-943.
9. Bradesi S., Eutamene H., Theodorou V., Fioramonti J., Bueno L. Effect of ovarian hormones on intestinal mast cell reactivity to substance P. Life Sci. 2001, 68(9):1047-1056.
10. Cao H., Zhang Y.Q. Spinal glial activation contributes to pathological pain states. Neurosci. Biobehav. Rev. 2008, 32(5):972-983.
11. Chen Z., Janes K., Chen C., Doyle T., Bryant L., Tosh D.K., Jacobson K.A., Salvemini D. Controlling murine and rat chronic pain through A3 adenosine receptor activation. FASEB J. 2012, 26(5):1855-1865.
12. Chen J.F., Eltzschig H.K., Fredholm B.B. Adenosine receptors as drug targets-what are the challenges?. Nat. Rev. Drug Discov. 2013, 12(4):265-286.
13. Costigan M., Moss A., Latremoliere A., Johnston C., Verma-Gandhu M., Herbert T.A., Barrett L., Brenner G.J., Vardeh D., Woolf C.J., et al. T-cell infiltration and signaling in the adult dorsal spinal cord is a major contributor to neuropathic pain-like hypersensitivity. J. Neurosci. 2009, 29(46):14415-14422.
14. Dixon A.K., Gubitz A.K., Sirinathsinghji D.J., Richardson P.J., Freeman T.C. Tissue distribution of adenosine receptor mRNAs in the rat. Br. J. Pharmacol. 1996, 118(6):1461-1468.
15. Doyle T., Chen Z., Muscoli C., Bryant L., Esposito E., Cuzzocrea S., Dagostino C., Ryerse J., Rausaria S., Kamadulski A., et al. Targeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic pain. J. Neurosci. 2012, 32(18):6149-6160.
16. Farquhar-Smith P. Chemotherapy-induced neuropathic pain. Curr. Opin. Support Palliat. Care 2011, 5(1):1-7.
17. Fishman P., Bar-Yehuda S., Barer F., Madi L., Multani A.S., Pathak S. The A3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp. Cell Res. 2001, 269(2):230-236.
18. Fishman P., Bar-Yehuda S., Madi L., Cohn I. A3 adenosine receptor as a target for cancer therapy. Anticancer Drugs 2002, 13(5):437-443.
19. Fishman P., Bar-Yehuda S., Ohana G., Barer F., Ochaion A., Erlanger A., Madi L. An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B. Oncogene 2004, 23(14):2465-2471.
20. Fishman P., Bar-Yehuda S., Liang B.T., Jacobson K.A. Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discovery Today 2012, 17(7-8):359-366.
21. Fredholm B.B., Jzerman A.P., Jacobson K.A., Klotz K.N., Linden J. International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 2001, 53(4):527-552.
22. Fredholm B.B., AP Jzerman, Jacobson K.A., Linden J., Muller C.E. International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors - an update. Pharmacol. Rev. 2011, 63(1):1-34.
23. Gallo-Rodriguez C., Ji X.D., Melman N., Siegman B.D., Sanders L.H., Orlina J., Fischer B., Pu Q., Olah M.E., van Galen P.J., et al. Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists. J. Med. Chem. 1994, 37(5):636-646.
24. Gao M., Yan X., Weng H.R. Inhibition of glycogen synthase kinase 3beta activity with lithium prevents and attenuates paclitaxel-induced neuropathic pain. Neuroscience 2013, 254:301-311.
25. Gessi S., Varani K., Merighi S., Cattabriga E., Avitabile A., Gavioli R., Fortini C., Leung E., Mac Lennan S., Borea P.A. Expression of A3 adenosine receptors in human lymphocytes: up-regulation in T cell activation. Mol. Pharmacol. 2004, 65(3):711-719.
26. Grace P.M., Rolan P.E., Hutchinson M.R. Peripheral immune contributions to the maintenance of central glial activation underlying neuropathic pain. Brain Behav. Immun. 2011, 25(7):1322-1332.
27. Hasko G., Szabo C., Nemeth Z.H., Kvetan V., Pastores S.M., Vizi E.S. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J. Immunol. 1996, 157(10):4634-4640.
28. Hayashida M., Fukuda K., Fukunaga A. Clinical application of adenosine and ATP for pain control. J. Anesth. 2005, 19(3):225-235.
29. Hershman D.L., Lacchetti C., Dworkin R.H., LavoieSmith E.M., Bleeker J., Cavaletti G., Chauhan C., Gavin P., Lavino A., Lustberg M.B., et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 2014, 32(18):1941-1967.
30. Hu P., Bembrick A.L., Keay K.A., McLachlan E.M. Immune cell involvement in dorsal root ganglia and spinal cord after chronic constriction or transection of the rat sciatic nerve. Brain Behav. Immun. 2007, 21(5):599-616.
31. Janes K., Little J.W., Li C., Bryant L., Chen C., Chen Z., Kamocki K., Doyle T., Snider A., Esposito E., et al. The development and maintenance of paclitaxel-induced neuropathic pain requires activation of the sphingosine 1-phosphate receptor subtype 1. J. Biol. Chem. 2014, 289(30):21082-21097.
32. Janes K., Doyle T., Bryant L., Esposito E., Cuzzocrea S., Ryerse J., Bennett G.J., Salvemini D. Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase. Pain 2013, 154(11):2432-2440.
33. Kannarkat G., Lasher E.E., Schiff D. Neurologic complications of chemotherapy agents. Curr. Opin. Neurol. 2007, 20(6):719-725.
34. Kiguchi N., Maeda T., Kobayashi Y., Saika F., Kishioka S. Involvement of inflammatory mediators in neuropathic pain caused by vincristine. Int. Rev. Neurobiol. 2009, 85:179-190.
35. Kreckler L.M., Wan T.C., Ge Z.D., Auchampach J.A. Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J. Pharmacol. Exp. Ther. 2006, 317(1):172-180.
36. Ledeboer A., Jekich B.M., Sloane E.M., Mahoney J.H., Langer S.J., Milligan E.D., Martin D., Maier S.F., Johnson K.W., Leinwand L.A., et al. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav. Immun. 2007, 21(5):686-698.
37. Lee J.Y., Jhun B.S., Oh Y.T., Lee J.H., Choe W., Baik H.H., Ha J., Yoon K.S., Kim S.S., Kang I. Activation of adenosine A3 receptor suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of PI 3-kinase/Akt and NF-kappaB activation in murine BV2 microglial cells. Neurosci. Lett. 2006, 396(1):1-6.
38. Little J.W., Chen Z., Doyle T., Porreca F., Ghaffari M., Bryant L., Neumann W.L., Salvemini D. Supraspinal peroxynitrite modulates pain signaling by suppressing the endogenous opioid pathway. J. Neurosci. 2012, 32(32):10797-10808.
39. Little J., Chen Z., Ford A., Janes K., Doyle T., Tosh D., Jacobson K., Salvemini D. (297) Central adenosine A3 receptor (A3AR) activation reverses neuropathic pain. J. Pain 2014, 15(4):S50.
40. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25(4):402-408.
41. Mabley J., Soriano F., Pacher P., Hasko G., Marton A., Wallace R., Salzman A., Szabo C. The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide, is protective in two murine models of colitis. Eur. J. Pharmacol. 2003, 466(3):323-329.
42. Madi L., Ochaion A., Rath-Wolfson L., Bar-Yehuda S., Erlanger A., Ohana G., Harish A., Merimski O., Barer F., Fishman P. The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin. Cancer Res. 2004, 10(13):4472-4479.
43. Madi L., Cohen S., Ochayin A., Bar-Yehuda S., Barer F., Fishman P. Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level. J. Rheumatol. 2007, 34(1):20-26.
44. Mannelli Di.Cesare., Pacini A., Bonaccini L., Zanardelli M., Mello T., Ghelardini C. Morphologic features and glial activation in rat oxaliplatin-dependent neuropathic pain. J. Pain 2013, 14(12):1585-1600.
45. Milligan E.D., Watkins L.R. Pathological and protective roles of glia in chronic pain. Nat. Rev. 2009, 10(1):23-36.
46. Moalem G., Xu K., Yu L. T lymphocytes play a role in neuropathic pain following peripheral nerve injury in rats. Neuroscience 2004, 129(3):767-777.
47. Moon H.G., Tae Y.M., Kim Y.S., Gyu Jeon S., Oh S.Y., Song Gho Y., Zhu Z., Kim Y.K. Conversion of Th17-type into Th2-type inflammation by acetyl salicylic acid via the adenosine and uric acid pathway in the lung. Allergy 2010, 65(9):1093-1103.
48. Obata K., Noguchi K. Contribution of primary sensory neurons and spinal glial cells to pathomechanisms of neuropathic pain. Brain Nerve 2008, 60(5):483-492.
49. Ochaion A., Bar-Yehuda S., Cohen S., Barer F., Patoka R., Amital H., Reitblat T., Reitblat A., Ophir J., Konfino I., et al. The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease. Cell. Immunol. 2009, 258(2):115-122.
50. Park S.S., Zhao H., Jang Y., Mueller R.A., Xu Z. N6-(3-iodobenzyl)-adenosine-5'-N-methylcarboxamide confers cardioprotection at reperfusion by inhibiting mitochondrial permeability transition pore opening via glycogen synthase kinase 3 beta. J. Pharmacol. Exp. Ther. 2006, 318(1):124-131.
51. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, San Diego.
52. Peters C.M., Jimenez-Andrade J.M., Kuskowski M.A., Ghilardi J.R., Mantyh P.W. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res. 2007, 1168:46-59.
53. Poulsen S.A., Quinn R.J. Adenosine receptors: new opportunities for future drugs. Bioorg. Med. Chem. 1998, 6(6):619-641.
54. Quasthoff S., Hartung H.P. Chemotherapy-induced peripheral neuropathy. J. Neurol. 2002, 249(1):9-17.
55. Randall L.O., Selitto J.J. A method for measurement of analgesic activity on inflamed tissue. Arch. Int. Pharmacodyn. Ther. 1957, 111(4):409-419.
56. Schneider C.A., Rasband W.S., Eliceiri K.W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 2012, 9(7):671-675.
57. Shankey T.V., Forman M., Scibelli P., Cobb J., Smith C.M., Mills R., Holdaway K., Bernal-Hoyos E., Van Der Heiden M., Popma J., et al. An optimized whole blood method for flow cytometric measurement of ZAP-70 protein expression in chronic lymphocytic leukemia. Cytom. Part B Clin. Cytom. 2006, 70(4):259-269.
58. Stemmer S.M., Benjaminov O., Medalia G., Ciuraru N.B., Silverman M.H., Bar-Yehuda S., Fishman S., Harpaz Z., Farbstein M., Cohen S., et al. CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. Oncologist 2013, 18(1):25-26.
59. Szabó C., Scott G.S., Virág L., Egnaczyk G., Salzman A.L., Shanley T.P., Haskó G. Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists. Br. J. Pharmacol. 1998, 125(2):379-387.
60. Tchilibon S., Joshi B.V., Kim S.K., Duong H.T., Gao Z.G., Jacobson K.A. (N)-methanocarba 2, N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists. J. Med. Chem. 2005, 48(6):1745-1758.
61. Tosh D.K., Deflorian F., Phan K., Gao Z.G., Wan T.C., Gizewski E., Auchampach J.A., Jacobson K.A. Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. J. Med. Chem. 2012, 55(10):4847-4860.
62. Varani K., Vincenzi F., Tosi A., Targa M., Masieri F.F., Ongaro A., De Mattei M., Massari L., Borea P.A. Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes. Br. J. Pharmacol. 2010, 160(1):101-115.
63. Varani K., Padovan M., Vincenzi F., Targa M., Trotta F., Govoni M., Borea P.A. A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release. Arthritis Res. Ther. 2011, 13(6):R197.
64. Velasco R., Bruna J. Chemotherapy-induced peripheral neuropathy: an unresolved issue. Neurologia 2010, 25(2):116-131.
65. Wang X.M., Lehky T.J., Brell J.M., Dorsey S.G. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine 2012, 59(1):3-9.
66. Watkins L.R., Milligan E.D., Maier S.F. Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. Adv. Exp. Med. Biol. 2003, 521:1-21.
67. Watkins L.R., Milligan E.D., Maier S.F. Spinal cord glia: new players in pain. Pain 2001, 93(3):201-205.
68. Xiao W.H., Zheng H., Bennett G.J. Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience 2012, 203:194-206.
69. Yoon S.Y., Robinson C.R., Zhang H., Dougherty P.M. Spinal astrocyte gap junctions contribute to oxaliplatin-induced mechanical hypersensitivity. J. Pain 2013, 14(2):205-214.
70. Zhang H., Yoon S.Y., Zhang H., Dougherty P.M. Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of paclitaxel-induced painful neuropathy. J. Pain 2012, 13(3):293-303.
71. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch. Pharmacol. 2000, 362(4-5):299-309.
72. Zylka M.J. Pain-relieving prospects for adenosine receptors and ectonucleotidases. Trends Mol. Med. 2011, 17(4):188-196.